A Win For Ocugen, Inc.

Ocugen, Inc. (OCGN:NASDAQ) jumped higher at $3.26, representing a gain of 80.1%. The stock got featured on our News Catalysts scanner on Tue 02 Feb 21 at 04:32 PM in the 'MISCELLANEOUS' category. From Tue 19 Jan 21, the stock recorded 33.33% Up Days and 30.00% Green Days

The stock spiked on Mon 04 Jan 21 at $3.5 with a volume of 169M+.

About Ocugen, Inc. (OCGN:NASDAQ)

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).